Wuhan Keqian Biology (688526) Fundamentals 2026 — P/E 15.0x, Revenue Analysis | SniperIQ
Wuhan Keqian Biology (688526) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥5.9B, trading at ¥12.58 on the SHH. This SniperIQ fundamentals page covers Wuhan Keqian Biology's valuation (P/E 15.0x, P/B 1.4x), profitability (net margin 41.8%), revenue (¥950M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Wuhan Keqian Biology's market cap?
Wuhan Keqian Biology (688526) has a market capitalization of approximately ¥5.9B, trading at ¥12.58 on the SHH. Market cap moves with the live share price.
What is Wuhan Keqian Biology's P/E ratio?
Wuhan Keqian Biology's trailing twelve-month P/E ratio is 15.0x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Wuhan Keqian Biology?
Wuhan Keqian Biology runs a net profit margin of 41.8%, a gross margin of 44.1%, and an operating margin of 43.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Wuhan Keqian Biology generate?
Wuhan Keqian Biology reported revenue of ¥950M for fiscal year 2025, with net income of ¥417M and earnings per share (EPS) of 0.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Wuhan Keqian Biology pay a dividend?
Wuhan Keqian Biology offers a trailing dividend yield of about 5.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Wuhan Keqian Biology financially healthy?
Wuhan Keqian Biology carries a debt-to-equity ratio of 0.00x and a current ratio of 7.42x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Wuhan Keqian Biology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Wuhan Keqian Biology (688526) the key facts are: market cap ¥5.9B, P/E 15.0x, revenue ¥950M, 52-week range 11.65-20.39. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Wuhan Keqian Biology's full fundamentals live
Get Wuhan Keqian Biology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.